Horizon Pharma plc Announces Issuance of VIMOVO(R) Related Patent with Protection to 2031 from United States Patent and Trademark Office
"This patent significantly expands the strength of the VIMOVO patent estate and extends patent protection out to 2031," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "In addition, this patent exhibits our commitment to innovation and ability to further strengthen the intellectual property protection of our portfolio of drugs. This is an important milestone in the commercial lifecycle for VIMOVO."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.